Okay, what am I missing here?
According to this article ...
hepatitiscnewdrugs.blogspot.com/2017/07/...da-approved-and.html
... Gilead filed for approval of Vosevi (Sof/Vel/Vox) on Dec 8, 2016 and is scheduled for decision on August 8, 2017.
And AbbVie filed for approval of MAVIRET (glecaprevir/pibrentasvir) on Dec 19, 2016 and is expected to get a decision on August 2, 2017.
First, why the discrepancy in timelines?
Second, are they giving Maviret with an NS5B or not?
Third, why no mention of the timeline of Merck's product?